Lasmiditan, also known as COL-144 and LY573144, is a novel, centrally acting, highly selective 5-HT(1F) receptor agonist (K1=2.21 μM) without vasoconstrictor activity that seemed effective when given as an intravenous infusion in a proof-of-concept migraine study. Lasmiditan showed efficacy in its primary endpoint, with a 2-hour placebo-subtracted headache response of 28.8%, though with frequent reports of dizziness, paresthesias, and vertigo.
5-HT Receptor Inhibitors Related Products:
RS-127445; Asenapine Maleate; WAY-100635 Maleate; WAY-100635 maleate salt; Vortioxetine; Vortioxetine hydrobromide; Blonanserin; Intepirdine; Sertraline HCl; Lamotrigine; Azasetron hydrochloride